{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:40:01Z","timestamp":1790883601485,"version":"4.1.0"},"reference-count":67,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Lung cancer is the leading cause of cancer\u2010related deaths worldwide. As new therapies are developed, it is important to understand the pulmonary toxicities associated with systemic lung cancer therapies. Cytotoxic chemotherapy regimens for NSCLC often include taxanes. Pulmonary toxicity from taxanes presents as an ILD\u2010type reaction characterized by increasing dyspnoea, dry cough, fever and bilateral pulmonary interstitial infiltrates. The incidence of taxane\u2010induced pneumonitis is rare, and many patients respond to steroid therapy; however, fatal cases have been reported. Patients with NSCLC are routinely tested for the presence of tumour oncogenes to determine their candidacy for targeted therapies, such as TKI. EGFR\u2010TKI can cause pneumonitis characterized by progressive dyspnoea and hypoxia. EGFR\u2010TKI\u2010associated ILD rarely presents as an AIP with rapidly progressive respiratory failure and high mortality rates. The most recent development in lung cancer therapy has been the discovery of immune checkpoint inhibitor (ICI). ICI pneumonitis has been increasingly recognized as a common complication of ICI therapy, with reported incidence as high as 19% in some clinical settings. Early\u2010grade ICI pneumonitis may be asymptomatic; however, high\u2010grade ICI pneumonitis can result in progressive dyspnoea, hypoxia and respiratory failure. ICI pneumonitis is unique in that only half of the patients will improve with steroid treatment, and mortality rates are high. As treatment of NSCLC evolves, providers must be able to recognize and respond to the development of drug\u2010induced pulmonary toxicities.<\/jats:p>","DOI":"10.1111\/resp.13915","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T04:08:35Z","timestamp":1596082115000},"page":"72-79","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Pulmonary toxicity of systemic lung cancer therapy"],"prefix":"10.1111","volume":"25","author":[{"given":"Kathryn","family":"Long","sequence":"first","affiliation":[{"name":"Division of Pulmonary Critical Care Medicine Johns Hopkins University School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2920-0949","authenticated-orcid":false,"given":"Karthik","family":"Suresh","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Critical Care Medicine Johns Hopkins University School of Medicine  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2017.1323580"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(93)90010-O"},{"key":"e_1_2_8_5_1","unstructured":"National Comprehensive Cancer Network. Version 2.2020: NCCN Clinical Practice Guidelines in Oncology: Non\u2010Small Cell Lung Cancer.2019. [Accessed 1 Jan 2020.] Available from URL:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"e_1_2_8_6_1","first-page":"1103","article-title":"Interstitial lung disease associated with docetaxel in patients with advanced non\u2010small cell lung cancer","volume":"32","author":"Tamiya A","year":"2012","journal-title":"Anticancer Res."},{"key":"e_1_2_8_7_1","first-page":"295","article-title":"Severe interstitial pneumonia induced by paclitaxel in a patient with adenocarcinoma of the lung","volume":"60","author":"Suzaki N","year":"2006","journal-title":"Acta Med. Okayama"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy180"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.5301\/tj.5000275"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008226416896"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10263"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-007-0106-4"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.2071"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10182"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-009-9391-9"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1648-2"},{"key":"e_1_2_8_17_1","first-page":"4357","article-title":"Carboplatin plus weekly paclitaxel treatment in non\u2010small cell lung cancer patients with interstitial lung disease","volume":"30","author":"Shukuya T","year":"2010","journal-title":"Anticancer Res."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14217"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(02)00145-9"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-007-9073-4"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00341-5"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.12.004"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.55.405"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.06.003"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602909"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.4.1031"},{"key":"e_1_2_8_27_1","first-page":"718","article-title":"Paclitaxel induced hypersensitivity pneumonitis: radiographic and CT findings","volume":"176","author":"Wong P","year":"2001","journal-title":"Am. J. Radiol."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1179\/1973947814Y.0000000189"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.16"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-4-303"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt049"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4526"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.06.032"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12550"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.014"},{"key":"e_1_2_8_36_1","doi-asserted-by":"crossref","unstructured":"MokTS WuYL AhnMJ GarassinoMC KimHR RamallngamSS ShepherdFA HeY AkamatsuH TheelenWSMEet al.;AURA3 Investigators. Osimertinib or platinum\u2010premetrexed in EGFR T790M\u2010positive lung cancer.N. Engl. J. Med.2017;376: 629\u201340.","DOI":"10.1056\/NEJMc1703339"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ca12e0"},{"key":"e_1_2_8_38_1","first-page":"e2805","article-title":"Afatinib\u2010induced interstitial lung disease successfully treated with corticosteroids: case report and review of the literature","volume":"10","author":"Jobe AL","year":"2018","journal-title":"Cureus"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0050"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.01.010"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.02.002"},{"key":"e_1_2_8_42_1","first-page":"68","article-title":"Successful osimertinib rechallenge after osimertinib\u2010induced pneumonitis in a patient with lung adenocarcinoma","volume":"23","author":"Satoh S","year":"2017","journal-title":"Respir. Med. Case Rep."},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.06.017"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.08.1048"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2453"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01430"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.09.015"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160221"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0735-0"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.04.177"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31043"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S136818"},{"key":"e_1_2_8_57_1","unstructured":"Common Terminology Criteria for Adverse Events Version 5.0.2017. [Accessed 22 Jan 2020.] Available from URL:https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.01.002"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S143939"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.016"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.02.011"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.001"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12759"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.02.018"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0058-2019"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128654"},{"key":"e_1_2_8_67_1","unstructured":"BrahmerJR LacchettiC SchneiderBJ AtkinsMB BrassilKJ CaterinoJM ChauI ErnstoffMS GardnerJM GinexPet al.;National Comprehensive Cancer Network. Management of immune\u2010related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.J. Clin. Oncol.2018;36:1714\u201398."},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fresp.13915","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.13915","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/resp.13915","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.13915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T18:52:29Z","timestamp":1693680749000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.13915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":67,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/resp.13915"],"URL":"https:\/\/doi.org\/10.1111\/resp.13915","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"2020-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}